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(See the editorial commentary by Lewis on pages 212–4)
Background. Voriconazole is the therapy of choice for aspergillosis and a new treatment option for candidiasis.
Liver disease, age, genetic polymorphism of the cytochrome CYP2C19, and comedications influence voriconazole
metabolism. Large variations in voriconazole pharmacokinetics may be associated with decreased efficacy or with
toxicity.
Methods. This study was conducted to assess the utility of measuring voriconazole blood levels with individ-
ualized dose adjustments.
Results. A total of 181 measurements with high-pressure liquid chromatography were performed during 2388
treatment days in 52 patients. A large variability in voriconazole trough blood levels was observed, ranging from
1 mg/L (the minimum inhibitory concentration at which, for most fungal pathogens, 90% of isolates are
susceptible) in 25% of cases to 15.5 mg/L (a level possibly associated with toxicity) in 31% of cases. Lack of
response to therapy was more frequent in patients with voriconazole levels 1 mg/L (6 [46%] of 13 patients,
including 5 patients with aspergillosis, 4 of whom were treated orally with a median dosage of 6 mg/kg per day)
than in those with voriconazole levels 11 mg/L (15 [12%] of 39 patients; ). Blood levels 11 mg/L werePp .02
reached after increasing the voriconazole dosage, with complete resolution of infection in all 6 cases. Among 16
patients with voriconazole trough blood levels 15.5 mg/L, 5 patients (31%) presented with an encephalopathy,
including 4 patients who were treated intravenously with a median voriconazole dosage of 8 mg/kg per day, whereas
none of the patients with levels 5.5 mg/L presented with neurological toxicity ( ). Comedication withPp .002
omeprazole possibly contributed to voriconazole accumulation in 4 patients. In all cases, discontinuation of therapy
resulted in prompt and complete neurological recovery.
Conclusions. Voriconazole therapeutic drug monitoring improves the efficacy and safety of therapy in severely
ill patients with invasive mycoses.
Voriconazole is the first choice therapy for invasive as-
pergillosis and is a new treatment option for candidi-
asis, other emerging invasive fungal infections (IFI),
such as fusariosis, and refractory IFI [1–5]. Status of
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the host immunity, localization and extension of in-
fection, early start of antifungal therapy, lack of re-
sponse to previous therapy, surgical management, and
in vitro antifungal susceptibility of the pathogen are
key determinants for a successful response [6–9]. The
role of antifungal drug blood concentrations with re-
spect to efficacy and safety is unclear. Liver metabolism
plays a key role in the disposition of voriconazole,
which acts simultaneously as a substrate and inhibitor
of multiple enzymes of the cytochrome P450 system
[7]. Multiple factors have been found to be associated
with a large variability in voriconazole exposure fol-
lowing standard dose administration, such as nonlinear
saturable pharmacokinetics, drug-drug interactions,
liver disease, patient age (in particular, with respect to
children), and genetic polymorphism of the cyto-
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chrome CYP2C19 [3, 7, 10, 11]. In experimental candidiasis,
the ratio of voriconazole peak concentration and the 24-h area
under the curve over the MIC have been identified as the best
pharmacodynamic predictors of treatment success [12]. In con-
trast, no experimental data are available regarding the phar-
macodynamics of voriconazole for the treatment of aspergillosis
or other mycoses. Some recent clinical observations have sug-
gested that under- and over-dosing of voriconazole may influ-
ence the efficacy and safety of therapy, respectively [1, 13–16].
Recently, experts have suggested that voriconazole trough blood
levels should be measured after 1 week of therapy for dose
adjustment to target values of 2–6 mg/L [7]. However, the utility
of such measurements remains debatable, given that multiple
confounding factors may influence the outcome of infection
and the assessment of tolerance in severely ill patients [17–19].
This uncertainty highlights the need for additional drug ex-
posure–related efficacy and safety data in patients treated with
voriconazole. The objective of the present observational study
was to assess the utility of voriconazole therapeutic drug mon-
itoring (TDM).
PATIENTS AND METHODS
Patients. All consecutive adult patients treated with voricon-
azole at a single university hospital during the period 2004–
2006 were identified from the pharmacy records. Patients who
received voriconazole with TDM were studied prospectively,
and those who received voriconazole without TDM were an-
alyzed retrospectively. Treating physicians based the choice of
voriconazole route and dose on the recommendations of the
package insert, published guidelines, and the literature [1, 2,
4, 20–22]. IFIs were classified as either proven, probable, or
possible according to definitions of the Invasive Fungal Infec-
tion Group of the European Organization for Research and
Treatment of Cancer and Mycoses Study Group of the National
Institute of Allergy and Infectious Diseases [23]. Empirical an-
tifungal therapy was given to patients with persistent febrile
neutropenia despite 196 h of broad-spectrum antibacterial
therapy. Demographic data, clinical characteristics, diagnosis of
IFI, and response to or experience of adverse events associated
with voriconazole therapy were recorded.
Response of infection to antifungal therapy. The assess-
ment of response to voriconazole therapy as partial or complete
was based on clinical (fever, signs and symptoms of infection,
and inflammatory markers) and radiological (CT or MRI find-
ings) improvement or resolution and on proven or presumed
eradication of the fungal pathogen [6]. Lack of response to
voriconazole therapy was defined by persistent IFI after 114
days of treatment or by progressing IFI (clinical and radiological
progression, persistently positive culture results, or death due
to IFI) after 17 days of treatment.
Safety of antifungal therapy. The type and severity of se-
vere adverse events and their causal relationship with voricon-
azole therapy were defined according to the criteria of the Na-
tional Cancer Institute [24].
Measurement of voriconazole blood levels. Voriconazole
trough blood levels were studied in citrated plasma by validated
high-pressure liquid chromatography (analytical range, 0.125–
25 mg/L) [25, 26]. Voriconazole trough levels were measured
because of the lack of clinical data on other pharmacodynamic
parameters that might better predict the efficacy and safety of
therapy and because routine blood sampling just preceding the
next voriconazole dose is practical and reliable for intrapatient
and interpatient comparisons. The therapeutic interval for vor-
iconazole troughs was 1–5.5 mg/L [1, 8, 13, 15, 27]. The choice
of the 1-mg/L cutoff value had been based on in vitro suscep-
tibility data (MIC90, 0.5–1 mg/L for the majority of fungal
pathogens), considering that only the free-circulating fraction
of voriconazole (i.e., 40%–50%) is microbiologically active and
available for penetration in infected organs [3, 8, 28, 29]. The
upper cutoff value was based on data reported for patients who
experienced adverse events [1, 13, 14, 30]. The following vor-
iconazole therapy modifications were proposed: (1) a 50% in-
crease in daily dose in patients with trough levels1 mg/L and
lack of response to therapy, as recommended in the package
insert, and (2) discontinuation of therapy in patients with
trough levels 15.5 mg/L plus/minus adverse events probably
related to overdosing.
Statistical analysis. Proportions were compared by the x2
test or Fisher’s exact test, as appropriate. Continuous variables
were compared by the nonparametric Mann-Whitney U test
or Kruskal-Wallis test, as appropriate. Statistical significance
was defined by a 2-sided P value !.05. The Spearman method
was used to study the correlation of 2 variables. A logistic
regression analysis (Stata software, version 8.2; Stata) was per-
formed to assess whether the log-transformed voriconazole
trough concentration is a significant predictor of response to
therapy (coded as success or lack of response) or safety (coded
as absence or presence of severe toxicity).
RESULTS
Patients. Among 96 adult patients treated with voriconazole
during the study period, 52 had TDM. All patients with TDM
were white; 51 (98%) of 52 were inpatients. The most frequent
underlying condition was acute myeloid leukemia with neu-
tropenia following myeloablative chemotherapy. Patients de-
mographic data and clinical characteristics are summarized in
table 1.
Data were analyzed retrospectively for 39 (89%) of 44 pa-
tients without voriconazole TDM; of these patients, 13 (33%)
were neutropenic, 21 (54%) had another type of immunosup-
pression, and 5 (13%) had no underlying condition.
Voriconazole therapy. A total of 2388 days of voriconazole
Table 1. Demographic and clinical characteristics, invasive fungal infec-
tions, and voriconazole therapy in 52 patients with therapeutic drug
monitoring.
Variable
Patients with
measured
voriconazole
blood levels
(n p 52)
Demographic data
Age, median years (range) 58.5 (23–78)
Sex, male:female 38 (73):14 (27)
Underlying condition
Hematological malignancy, neutropenia !0.5 g/L 32 (61)
Solid-organ transplantation 3 (6)
Abdominal surgery 3 (6)
Chronic liver disease 3 (6)
Other conditiona 7 (13)
None 4 (8)
Fungal infection
Proven or probable invasive aspergillosisb 26 (50)
Lung 19 (36)
Sinusc 3 (6)
Disseminatedd 3 (6)
Intra-abdominal 1 (2)
Proven or probable invasive candidiasise 8 (15)
Bloodstream 3 (6)
Hepatosplenic 4 (7)
Bone 1 (2)
Other proven invasive fungal infection (Pseudallescheria boydii and
Paecilomyces species): bone 2 (4)
Possible invasive fungal infection: lung 11 (21)
Persistent fever during neutropenia 5 (10)
Voriconazole therapy
First line 33 (64)
Second line 19 (36)
Failure of first-line therapy 1 (2)
Intolerance to first-line therapy 9 (17)
Switch from intravenous to oral therapy 9 (17)
Route of administration
Intravenous 40 (77)
Switch from intravenous to oral therapy 17 (33)
Oral 12 (23)
Voriconazole daily dose, median mg/kg/day (range)
Loading dose (oral or intravenous) 12
Maintenance dose
Intravenous 8 (6–11)
Oral 6.5 (2–11)f
Duration of therapy, median days (range)
Overall 50 (4–1130)
Intravenous 6.5 (4–30)
Oral 55 (5–1130)
NOTE. Data are no. (%) of patients, unless otherwise indicated.
a Chronic lung disease (2 patients), diabetes mellitus (2 patients), HIV infection (2 pa-
tients), and open knee fracture (1 patient).
b Proven aspergillosis (19 patients) and probable aspergillosis (7 patients).
c With intracerebral extension (1 patient).
d Involvement of lung (3 patients), sinus (2 patients), liver (2 patients), and skin (1 patient).
e Proven candidiasis (4 patients) and probable candidiasis (4 patients).
f Intravenous vs. oral maintenance daily dose ( ).Pp .07
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Figure 1. Relationship between voriconazole dosage and voriconazole
trough blood level. Each point represents a single blood level measure-
ment. Numbers of measurements for each daily dose are reported. Hor-
izontal bars represent median values (the numerical values are reported
on the right of the horizontal bar for each group). Voriconazole dosages
have been rounded to the nearest unit.
therapy in 52 patients with TDM were studied. Types and sites
of IFI and data on therapy are summarized in table 1.
Among 39 patients without voriconazole TDM, 31 (79%)
were treated for aspergillosis (6 proven cases, 16 probable cases,
and 9 possible cases), 2 (5%) were treated for proven candi-
diasis, and 6 (16%) were treated for persistent febrile neutro-
penia. Patients received voriconazole intravenously in 9 (23%)
of the cases, intravenously followed by orally in 12 (31%), and
orally in 18 (46%). The voriconazole loading dosage was 12
mg/kg per day, and the median maintenance dosage was 6.5
mg/kg per day (range, 5–8 mg/kg per day). The median du-
ration of therapy was 30 days (range, 7–365 days).
Measurements of voriconazole trough blood levels. A total
of 181 voriconazole trough levels were measured (median num-
ber per patient, 4.5; range, 1–9). The median time interval
between dose administration and measurement of trough levels
was 12 h (range, 11–13 h). The first trough levels were measured
at a median of 5 days (range, 3–46 days) after starting therapy.
The median time elapsed between consecutive blood level mea-
surements was 7 days (range, 1–62 days). Figure 1 shows the
trough levels in patients receiving different voriconazole daily
doses. A large intradose variability in voriconazole levels was
observed. No significant difference was found among trough
levels at different daily doses, nor was any correlation between
daily doses and trough levels observed ( ). During2r p 0.07
therapy with identical daily doses in 13 patients, the intrain-
dividual variability of trough levels was substantial. In 5 pa-
tients, levels increased (median increase, 61%; range, 22%–
125%; 1 patient had an increase 1100%); in 8 patients, levels
decreased (median decrease, 52%; range, 42%–84%; 4 patients
had a decrease 150%).
Response of infection to voriconazole therapy. At the time
of clinical assessment, voriconazole trough levels were 1 mg/
L in 13 cases (25%) and 11 mg/L in 39 cases (75%). A sig-
nificantly higher proportion of patients with levels 1 mg/L
received oral voriconazole. Lack of response to therapy was
more frequently observed in patients with levels 1 mg/L
(46%) than in those with levels 11 mg/L (12%; ) (tablePp .02
2). Among patients with levels 1 mg/L, the characteristics of
those with lack of response (6 patients) and those responding
to therapy (7 patients) were compared. Immunosuppression
was present in 5 (83%) of 6 and 5 (71%) of 8 patients, re-
spectively. Aspergillosis was diagnosed in 5 patients (83%; 3
patients received a diagnosis of extrapulmonary aspergillosis)
and 4 patients (57%; no patients received a diagnosis of ex-
trapulmonary aspergillosis), respectively. The clinical course of
6 patients with persistence or progression of IFI and voricon-
azole levels 1 mg/L is shown in table 3. In all 6 patients, IFI
responded after an increase in voriconazole doses (no antifun-
gal agent was added to the treatment regimen). Neutropenia
resolved in 2 patients (after clinical response of IFI in 1 patient);
immunosuppression persisted in 3 patients (in 1 patient re-
ceiving azathioprine and/or corticosteroids, 1 patient with
AIDS, and 1 patient with liver cirrhosis), and 1 patient was not
immunocompromised.
Among the 5 patients with voriconazole levels 11 mg/L (me-
dian voriconazole level, 4.1 mg/L; range, 2.4–9 mg/L) and lack
of response to therapy, 1 had probable invasive candidiasis, 1
had probable invasive aspergillosis, 2 had possible IFI, and 1
had breakthrough PCR-proven zygomycosis. In 4 cases, treat-
ment was switched to a salvage regimen (1 patient received
caspofungin, 2 received liposomal amphotericin B, and 1 re-
ceived a combination of both agents) after a median of 9 days
of voriconazole therapy (range, 4–21 days). Three patients had
complete resolution of IFI (median duration of follow-up, 60
days; range, 45–60 days), and 2 patients died due to IFI (after
5 and 7 days, respectively).
The logistic regression analysis indicated that the log-trans-
formed voriconazole trough level is a significant predictor of
response to therapy: a 2-fold increase in blood level is associated
with an OR for success of 1.8 (95% CI, 1.1–3.1; ). ThePp .03
logistic regression model indicates a 70% probability of re-
sponse at a voriconazole trough concentration of 1 mg/L (figure
2A).
Among the 39 patients without voriconazole TDM, 9 patients
(1 with proven, 5 with probable, and 3 with possible IFI) did
not respond to therapy (no MIC data were available). For 3
patients, voriconazole doses were increased (2 patients re-
sponded, and there was no follow-up in 1 patient); in 2 patients,
therapy was switched to a salvage regimen (1 patient responded,
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Table 2. Voriconazole trough blood levels and clinical response to antifungal therapy.
Variable
Voriconazole trough
blood level
P
1 mg/L
(n p 13)
11 mg/L
(n p 39)
Route of voriconazole administration .05
Intravenous 4 (31) 24 (61)
Oral 9 (69) 15 (39)
Voriconazole dosage, median mg/kg/day (range)
Overall 7 (2.5–9) 8 (2–11) NS
Intravenous 7.5 (7–8) 8 (6–11) NS
Oral 6 (2.5–9) 7 (2–11) NS
Response to antifungal therapy
Interval between start of voriconazle therapy and assessment, median days (range) 21 (10–120) 17.5 (10–180) NS
Treatment success
Overall 7 (54)a 34 (88) .02
Complete response 5 27
Partial response 2 7
Lack of response 6 (46) 5 (12)
Persistence 3 (23) 0 (0)
Progression 3 (23) 4 (10)
Breakthrough IFI 0 (0) 1 (2)
NOTE. Data are no. (%) of patients, unless otherwise indicated. NS, not significant.
a In 1 patient, comedication with rifampin resulted in low voriconazole blood levels.
and 1 patient died of refractory IFI); and in 4 patients, therapy
remained unchanged (all 4 patients died of refractory IFI).
Safety of voriconazole therapy. Voriconazole trough lev-
els were 5.5 mg/L in 36 patients (69%) and 15.5 mg/L in
16 patients (31%) (table 4). The majority of patients with
voriconazole levels 15.5 mg/L received voriconazole intra-
venously, and a significant proportion of these patients re-
ceived omeprazole comedication. Five serious neurological
adverse events (National Cancer Institute grade 3) were ob-
served in patients with voriconazole levels 15.5 mg/L (31%),
compared with none among patients with levels 5.5 mg/L
(0%; ). The clinical characteristics and the course ofPp .002
adverse events in these patients are summarized in table 5.
When patients with trough levels 15.5 mg/L with and without
toxicity were compared, voriconazole daily doses, route of
administration, and blood levels were similar (data not
shown). Absence of other causes and prompt and complete
neurological recovery after therapy discontinuation suggest
the probable relationship between these encephalopathies and
voriconazole overdosing. The logistic regression analysis con-
firmed a significant association between voriconazole trough
concentrations and neurotoxicity: the OR for severe toxicity
after a 2-fold increase of voriconazole levels in blood was 284
(95% CI, 0.96–84,407; ). The estimated probability ofPp .05
neurotoxicity at voriconazole trough levels of 5.5 mg/L and
8 mg/L was 15% and 90%, respectively (figure 2B).
A severe cholestasic hepatopathy (defined as 10 times the
baseline or 3 times the baseline, if the baseline was 13 times
the upper limit of normal) occurred in 6 patients (2 with pre-
existing hepatopathy). These events were observed in 8% of
patients with voriconazole levels 5.5 mg/L and in 19% of
those with levels 15.5 mg/L (the difference was not statistically
significant). Although this toxicity was possibly or probably
related to voriconazole, no correlation was found between vor-
iconazole trough levels and alkaline phosphatase ( )2r p 0.01
or g-glutamyl transpeptidase ( ). Voriconazole dose2r p 0.01
was reduced by 50% in 4 cases: cholestatic parameters remained
110 times the upper limit of normal in 2 patients and decreased
to 5 times the upper limit of normal in 2 patients. After dis-
continuation of voriconazole, cholestasis decreased to 3–5 times
the upper limit of normal in all patients within a median of
20 days (range, 10–30 days). In 2 patients who had long-term
follow-up (10 and 12 months), the liver parameters remained
elevated despite the absence of a pre-existing hepatopathy. The
logistic regression analysis failed to demonstrate a significant
association between voriconazole levels and hepatotoxicity; the
OR for hepatotoxicity of a 2-fold increase in voriconazole levels
was 1.4 (95% CI, 0.7–3).
Among 39 patients without voriconazole TDM, 7 (18%)
experienced serious adverse events possibly related to therapy
(2 of which were neurological and 5 of which were hepatic).
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Table 4. Voriconazole (Vor) trough blood levels and safety of antifungal therapy.
Variable
Vor trough blood level
P
5.5 mg/L
(n p 36)
15.5 mg/L
(n p 16)
Vor route .07
Intravenous 15 (42) 13 (81)
Oral 21 (58) 3 (19)
Vor dosage, median mg/kg/day (range)
Overall 7 (2–11) 8 (6–11) .13
Intravenous 7.5 (6–10) 8 (6–11) NS
Oral 6 (2–11) 7 (6–8) NS
Serious adverse event
Encephalopathy
Incidence 0 5 (31) .002
Interval after start of Vor, days (range) NA 9 (5–30)a
Cholestatic hepatopathy
Incidence 3 (8) 3 (19) NS
Interval after start of Vor, days (range) 50 (5–150) 13 (6–20) NS
Concomitant therapy
Omeprazole 6 (17) 7 (44) .04
Tacrolimus 0 1 (6) NS
NOTE. Data are no. (%) of patients, unless otherwise indicated.
a The time interval elapsed between start of Vor therapy and documentation of Vor blood levels 15.5
mg/L in patients without encephalopathy was a median of 5 days (range, 2–7 days); , vs. timePp .04
interval in patients with encephalopathy.
The 2 patients with neurological symptoms completely recov-
ered after discontinuation of voriconazole.
DISCUSSION
We report the experience with voriconazole TDM during 2388
treatment-days in 52 white adult patients. A large variability in
voriconazole trough levels was observed: voriconazole trough
levels were 1 mg/L in 13 (25%) of the patients (the majority
of whom were receiving oral therapy) and 15.5 mg/L in 16
(31%) (the majority of whom were receiving intravenous ther-
apy). This observation is consistent with previous reports [16,
27, 31]. Intravenous daily doses were higher than oral daily
doses. Confounding factors—such as drug-drug interactions,
liver disease, and polymorphism of cytochrome CYP2C19—
may have influenced voriconazole metabolism in some indi-
viduals. Among white individuals, 26% of heterozygous exten-
sive metabolizers (who experienced 2-fold voriconazole
exposure, compared with homozygous extensive metabolizers)
and 2% of homozygous poor metabolizers (who experienced
4-fold exposure) have been described [10, 27]. CYP2C19 ge-
notype was not determined in the present study.
Persistence or progression of IFI was observed in a signifi-
cantly higher proportion of patients with voriconazole trough
concentrations 1 mg/L, compared with patients with trough
concentrations 11 mg/L. The association between trough levels
and response to antifungal therapy was confirmed in a logistic
regression model. No fungal in vitro resistance was documented
as a cause of treatment failure. No difference in immunosup-
pressive conditions was found. In all cases involving a lack of
response at low voriconazole levels, an increase in voriconazole
doses resulting in levels 11 mg/L was successful. The choice of
the 1-mg/L cutoff value for voriconazole trough concentrations
had been based on (1) in vitro susceptibility data (MIC90, 0.5–
1 mg/L for the majority of pathogenic fungi), (2) the fact that
only the free-circulating fraction of voriconazole (40%–50%)
is microbiologically active and penetrates infected tissues, (3)
the fact that blood sampling just preceding the next voricon-
azole dose is practical and reliable for intrapatient and inter-
patient comparisons, and (4) the lack of clinical data on other
pharmacodynamic parameters that might better predict efficacy
and safety [3, 8, 28, 29]. Patients with voriconazole levels 1
mg/L received oral treatment more frequently than did those
with levels 11 mg/L. Variability in oral bioavailability associated
with meals and hepatic first-pass effect might have contributed
to lower exposure [1, 13, 27]. Degradation of oral voriconazole
by intestinal cytochrome enzymes may contribute to impaired
drug absorption: the reversing effect on this phenomenon of
grapefruit juice has been associated with improved bioavaila-
bility in mice [32]. No drug-drug interaction could be identified
in patients with voriconazole underexposure. In 2 patients, the
recommended oral dosage not adjusted for body weight (200
mg twice per day) was lower than the intravenous dosage (4
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Figure 2. Voriconazole trough blood levels and logistic regression
model for response to antifungal therapy (A) and for neurotoxicity (B).
The symbols represent the voriconazole levels observed in each individual
patient with treatment success (top) or lack of response to therapy
(bottom) and with (top) or without (bottom) signs of neurological toxicity.
The continuous line represents the logistic regression model predicting
the probability of response to antifungal therapy (A) or neurotoxicity (B)
as a function of the voriconazole trough blood concentration. The vertical
dotted lines indicate the proposed 1–5.5-mg/L therapeutic interval of
voriconazole.
mg/kg twice per day). Our data confirm and extend previous
observations that low voriconazole levels may impair the re-
sponse of IFI to therapy. The US Food and Drug Administra-
tion’s voriconazole briefing document reports a pharmacoki-
netic/pharmacodynamic analysis involving 280 cases of proven
or probable IFI that suggests a trend to higher success rates in
patients with mean voriconazole levels 10.5 mg/L (136 [56%]
of 245 patients), compared with patients with levels !0.5 mg/
L (16 [46%] of 35 patients; OR, 1.5; 95% CI, 0.6–3.4) [27]. In
an open-label, multicenter trial of voriconazole for first-line or
salvage therapy in 116 patients with aspergillosis, 6 treatment
failures among 11 patients with mean voriconazole levels !0.5
mg/L were observed [1]. A relationship between voriconazole
levels randomly measured during the dosing interval and treat-
ment success was described in 28 patients with IFI: there was
a 100% treatment response rate in patients with voriconazole
levels 12 mg/L and a 56% response rate in patients with vor-
iconazole levels !2 mg/L [15]. Among a group of 8 critically
ill patients who received voriconazole via a nasogastric tube, 2
treatment failures that were possibly associated with low blood
levels of voriconazole were observed [33]. Six breakthrough
IFIs occurred during voriconazole prophylaxis in a group of
43 allogeneic hematopoietic stem cell transplant recipients with
voriconazole trough concentrations !2 mg/L, and none oc-
curred in a group of 24 such patients with voriconazole trough
concentrations 12 mg/L [34]. These data are consistent with
the exposure-response relationship recently described for po-
saconazole, another new-generation triazole [35].
Safety issues were also found to be associated with the var-
iability of voriconazole blood levels. We observed a toxic en-
cephalopathy in one-third of patients with trough levels 15.5
mg/L after 11 week of therapy. The association between over-
dosing and neurotoxicity was confirmed in a logistic regression
model. These persistent or worsening neurological manifesta-
tions, which differed from transient and spontaneously resolv-
ing disturbances of light perception reported in 20%–25% of
patients, promptly resolved after discontinuation of therapy.
Moreover, in patients with high levels of voriconazole and no
neurological symptoms or signs, prompt dose reduction or dis-
continuation of voriconazole might have prevented toxicity by
limiting the duration of overexposure. The majority of patients
with blood levels 15.5 mg/L were treated intravenously, with a
trend towards higher daily doses. Drug-drug interactions, in
particular with omeprazole, may have played a role in vori-
conazole overdosing [27, 36, 37]. The severe cholestasis that
developed during therapy might also have contributed to vor-
iconazole accumulation. Two studies have described visual hal-
lucinations in 4% of cases and encephalopathy in 1% of cases
during voriconazole therapy. However, no data on voriconazole
levels were reported [2, 22]. Another trial reported voriconazole
trough levels 110 mg/L in 6 (5%) of 116 patients, all of whom
required discontinuation of therapy: in 3 (50%) of 6 patients,
toxicity possibly related to overdosing was described [1, 13, 17].
Other investigators reported a significant association between
visual adverse events and voriconazole levels; the rate of such
events was 18% among patients with trough concentrations !1
mg/L and 31% among those with trough concentrations 19
mg/L [38]. Six neurological adverse events were described
among a group of 28 patients; the hazard ratio was 2.3 (95%
CI, 1.4–3.6) per 0.1 mg/L increase in voriconazole trough level
[14]. A patient with liver cirrhosis treated with voriconazole (4
mg/kg per day) and pantoprazole developed coma while the
voriconazole trough level was 13.9 mg/L and then rapidly re-
covered when the voriconazole level decreased to !10 mg/L
after therapy discontinuation [30].
Abnormal liver function test results have been reported in
1%–10% of patients receiving voriconazole [22, 27, 39]. In our
study, severe hepatic toxicity occurred independently of vori-
210 • CID 2008:46 (15 January) • Pascual et al.
conazole levels. This finding confirms other observations, which
reported only a weak correlation, if any, between voriconazole
exposure and severity of hepatotoxicity [14, 16, 18, 27, 31, 38].
The lack of a prospective study design with systematic vor-
iconazole TDM at fixed time points is a limitation of the present
study. However, similar clinical observations in patients without
TDM suggest that the reported experiences are representative
of individuals receiving voriconazole. No IFI with a voricon-
azole MIC of 1–4 mg/L was documented. In patients with such
infections, individualized dose adjustments targeting voricon-
azole trough levels exceeding these values may be required [3].
In conclusion, the present study shows the importance of
voriconazole TDM in severely ill patients with invasive mycoses
[7, 17]. Multiple intrinsic and extrinsic factors may unpre-
dictably influence voriconazole pharmacokinetics. Because it is
difficult to clinically identify individuals with inappropriate ex-
posure, dose adjustment after documentation of low or high
voriconazole levels is critical if infection is not responding to
treatment or if toxicity is suspected. Moreover, detection of
voriconazole trough levels outside the therapeutic interval of
1–5.5 mg/L during the first week of therapy may prevent treat-
ment failures and neurological toxicity. Prospective trials in-
cluding voriconazole TDM are needed.
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